Literature DB >> 14596628

Heartburn in patients with gastro-oesophageal reflux disease in Germany and Sweden: a study on patients' burden of disease.

Roger Jones1, Silke Horbach, Peter Sander, Tina Rydén-Bergsten.   

Abstract

BACKGROUND: Gastro-oesophageal reflux disease (GORD) is widespread in the general population and presents in most cases with heartburn as the main symptom. The severity of symptoms is not necessarily related to erosive damage to the oesophagus due to acid reflux, but the frequency and severity of symptoms have an impact on the health-related QOL (HR-QOL) of the patient.
OBJECTIVE: To characterise patients with GORD who consult a physician because of heartburn with respect to medical background and burden of disease in Germany and Sweden.
METHODS: A total of 1011 patients who had been experiencing symptoms of GORD, including heartburn, for at least 1 year were recruited by physicians, who collected data on the patients' previous diagnosis and treatment. The patients themselves were interviewed by telephone about their heartburn. The EuroQOL 5-dimensional HR-QOL questionnaire (EQ-5D) and the Gastrointestinal Symptom Rating Scale (GSRS) were used to measure patient-reported outcomes.
RESULTS: About half of the patients had been experiencing symptoms of GORD for >5 years. The majority (54%) perceived the severity of their heartburn as moderate. Thirty-eight percent of the patients had been examined by endoscopy during the last 12 months and 79% of these had macroscopic oesophagitis. Medical treatment for heartburn had been prescribed to 88% of the patients. The mean annual number of days with heartburn was assessed as 170 days per patient, with the majority of patients (64%) experiencing heartburn every week. HR-QOL was reduced in these patients as expressed by EQ-5D scores compared to scores for a general population. Patients with GORD had problems related to gastrointestinal symptoms as rated by GSRS scores. More severe heartburn was associated with a greater number of symptom days and reduced HR-QOL scores, whereas a relationship between the findings at endoscopy and the severity of symptoms or HR-QOL could not be found.
CONCLUSION: This study demonstrates that heartburn confers a significant burden on patients with GORD, related to the frequency and severity of symptoms and reflected in the reduction in HR-QOL as perceived by the patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14596628     DOI: 10.2165/00019053-200321150-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  34 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

3.  Comparison of Euroqol EQ-5D and SF-36 in patients with chronic fatigue syndrome.

Authors:  C Myers; D Wilks
Journal:  Qual Life Res       Date:  1999       Impact factor: 4.147

4.  Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease.

Authors:  D A Revicki; M Wood; I Wiklund; J Crawley
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

Review 5.  Gastroesophageal reflux disease: diagnosis and management.

Authors:  M Scott; A R Gelhot
Journal:  Am Fam Physician       Date:  1999-03-01       Impact factor: 3.292

Review 6.  Symptom and health-related quality-of-life measures for use in selected gastrointestinal disease studies: a review and synthesis of the literature.

Authors:  A M Rentz; C Battista; E Trudeau; R Jones; P Robinson; S Sloan; S Mathur; L Frank; D A Revicki
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 7.  Quality of life in different gastrointestinal conditions.

Authors:  I K Wiklund; H Glise
Journal:  Eur J Surg Suppl       Date:  1998

8.  Three year follow up of patients with gastrooesophageal reflux disease.

Authors:  N E Schindlbeck; A G Klauser; G Berghammer; W Londong; S A Müller-Lissner
Journal:  Gut       Date:  1992-08       Impact factor: 23.059

Review 9.  Gastroesophageal reflux disease.

Authors:  P O Katz
Journal:  J Am Geriatr Soc       Date:  1998-12       Impact factor: 5.562

Review 10.  Defining GERD.

Authors:  S J Sontag
Journal:  Yale J Biol Med       Date:  1999 Mar-Jun
View more
  2 in total

1.  Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.

Authors:  Zhuolin Zhang; Yuwen Bao; Lele Cai; Yajie Gu; Ting Yang; Xin Li
Journal:  Clin Drug Investig       Date:  2022-08-22       Impact factor: 3.580

2.  Correlation Between Symptom Severity and Health-Related Life Quality of a Population With Gastroesophageal Reflux Disease.

Authors:  Shou-Wu Lee; Teng-Yu Lee; Han-Chung Lien; Yen-Chun Peng; Hong-Jeh Yeh; Chi-Sen Chang
Journal:  Gastroenterology Res       Date:  2017-04-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.